The National Center for Advancing Translational Sciences, an institute of the National Institutes of Health in the Department of Health and Human Services, has entered into a Cooperative Research and Development Agreement for the continued development of NES100 (Virpax Pharmaceuticals), an intranasal peptide being studied as a treatment for the management of acute and chronic noncancer pain.